OTCMKTS:CRXM Gene Biotherapeutics (CRXM) Stock Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free CRXM Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2,500 shsAverage Volume5,002 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Gene Biotherapeutics alerts: Email Address Ad Porter & CompanyObama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here About Gene Biotherapeutics Stock (OTCMKTS:CRXM)Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.Read More Ad Porter & CompanyObama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here CRXM Stock News HeadlinesMay 17 at 8:51 PM | msn.comUCLA academic senate rejects censure and 'no confidence' vote on Chancellor Gene BlockMay 17 at 3:50 PM | msn.comChris Klieman, Gene Taylor discuss K-State’s trip to IrelandMay 17 at 12:00 AM | omaha.comNew sculpture unveiled at Omaha's Gene Leahy MallMay 16 at 6:59 PM | msn.comNew sculptures on display at Omaha’s Gene Leahy MallMay 16 at 1:10 PM | markets.businessinsider.comBuy Rating Reaffirmed for Taysha Gene Therapies Amid Promising Clinical and Financial ReportsMay 16 at 1:10 PM | forbes.comHow Gene Editing Therapies Could Go Beyond Rare DiseasesMay 16 at 3:09 AM | msn.comEmotionally charged courtroom as Gene Meyer murder trial gets underwayMay 16 at 3:09 AM | msn.comOpenAI Chief Scientist That Quit Months After Participating In Coup Against Sam Altman, Likely To Join Elon Musk's xAI, Says Gene Munster: 'There's A 60% Chance'May 15 at 5:08 PM | msn.comWATCH: Gene Snitsky Re-Enacts Infamous WWE Spot Of Punting A Baby At Indie ShowMay 15 at 5:08 PM | msn.comEx-WWE Star Gene Snitsky Punts A Baby (Again!) At 'The Last Match' Rock ExperienceMay 15 at 9:48 AM | finance.yahoo.comCell and Gene Therapy Manufacturing Research Report 2024May 15 at 4:48 AM | finance.yahoo.comTaysha Gene Therapies Inc (TSHA) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 15 at 4:48 AM | finance.yahoo.comGenomic Cancer Panel and Profiling Market Report 2024. by Cancer, by Application, by Tissue and by Gene Type with Screening Potential Market SizeMay 14, 2024 | msn.comGoogle Is 6 Months Behind ChatGPT-Parent OpenAI In Artificial Intelligence But 'About 5 Years Ahead Of Everyone Else,' Says Gene MunsterMay 14, 2024 | markets.businessinsider.comStrong Buy Recommendation for Taysha Gene Therapies Based on Upcoming TSHA-102 Data and Market PotentialMay 14, 2024 | markets.businessinsider.comHere's what to expect from Taysha Gene Therapies's earnings reportMay 14, 2024 | msn.comPatient Dies After Receiving Kidney From Gene-Hacked PigMay 13, 2024 | yahoo.com2024 Zip Trip season: Gene, Shiri reveal the 8 spots we’ll be visiting this summerMay 13, 2024 | msn.comGene Autry VFD hosts annual fish fry fundraiser to upgrade fire stationMay 12, 2024 | barrons.comFirst Patient To Get Gene-edited Pig Kidney Transplant DiesMay 12, 2024 | msn.comOutgoing Ohio State AD Gene Smith believes Michigan wins over Ohio State should have asterickMay 12, 2024 | barrons.comFirst Patient To Get Gene-edited Pig Kidney Transplant Dies: HospitalMay 11, 2024 | cbsnews.comUCLA Chancellor Gene Block faces censure, no-confidence vote as graduation ceremonies startMay 10, 2024 | msn.comBreakthrough Gene Therapy Enables Infant Born Deaf to HearMay 10, 2024 | msn.comGene Lang was the best player to wear No. 33 for the BroncosSee More Headlines Receive CRXM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gene Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:CRXM Previous SymbolNYSE:CXM CUSIPN/A CIK772320 Webwww.cardiumthx.com Phone(858) 414-1477Fax858-436-1001Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Christopher J. Reinhard (Age 70)Co-Founder, CEO, President, Treasurer & Director Comp: $240kMr. James L. Grainer (Age 69)Chairman, CFO & Secretary Dr. Lois A. Chandler (Age 66)Chief Operating Officer Dr. Ronald J. Shebuski (Age 71)Chief Scientific Officer Mr. Duane LinstromGeneral CounselKey CompetitorsAdvanced Life SciencesOTCMKTS:ADLSAlvotechNYSE:ALVOAVAX TechnologiesOTCMKTS:AVXTClarus TherapeuticsOTCMKTS:CRXTQEnzon PharmaceuticalsOTCMKTS:ENZNView All Competitors CRXM Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Gene Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gene Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Adaptimmune Therapeutics (ADAP), Intellipharmaceutics International (IPCIF), MGT Capital Investments (MGTI) and Nokia Oyj (NOK). How do I buy shares of Gene Biotherapeutics? Shares of CRXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CRXM) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBill Clinton Backing Biden Replacement???The Freeport SocietyUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gene Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.